Telesis Bio

Telesis Bio LT Debt/Equity

Delisted·Oct 6, 2026

The Long-Term Debt to Equity Ratio of Telesis Bio (TBIO) as of Nov 14, 2026 is 0.18. In the previous year, Long-Term Debt to Equity Ratio was 0.42 — a change of -57.73% (lower).

LT Debt/Equity

0.18

YoY

-57.73%

Last updated:

Long-Term Debt to Equity Ratio of Telesis Bio is 2023 0.18 . Long-Term Debt to Equity Ratio of Telesis Bio was 2022 0.42 . It decreases by -57.73% lower compared to the previous year.

The Telesis Bio LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2019
-0.60 USD
Jan 1, 2020
-0.13 USD
Jan 1, 2021
0.16 USD
Jan 1, 2022
0.42 USD
Jan 1, 2023
0.18 USD
The Telesis Bio LT Debt/Equity history
YEARLT Debt/EquityYoY
0.18-57.73%
0.42+171.92%
0.16-217.83%
-0.13-77.90%
-0.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Codex DNA, Inc. develops genomic tools for biomedical and industrial applications, focusing on synthetic biology solutions to overcome bottlenecks in DNA and mRNA production. Its BioXp systems, including the BioXp 3250, serve as end-to-end automated workstations, while BioXp kits generate synthetic DNA and mRNA. The company offers 14 SARS-CoV-2 full-length genomes, RNA controls, and Vmax X2 cells as part of its product portfolio. BioXp systems are placed globally with approximately 200 units deployed. The firm targets researchers and biotech companies needing scalable DNA and mRNA synthesis, leveraging its automated workflow solutions. Products like BioXp kits and benchtop reagents complement the core systems, addressing limitations in current solutions. The company has launched eight BioXp kits and three benchtop reagent kits, supporting applications across biomedical and industrial sectors. Revenue streams come from selling BioXp systems, kits, and reagents directly to research institutions and biotechnology firms. The BioXp 3250 system, BioXp kits, and benchtop reagent kits are key products driving sales. Vmax X2 cells and SARS-CoV-2 related products also contribute to the company's revenue. Global deployment of 200 BioXp systems indicates strong market adoption among customers in the synthetic biology space. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Long-Term Debt to Equity Ratio of Telesis Bio is 0.18 in 2023.

Long-Term Debt to Equity Ratio of Telesis Bio changed from 0.42 to 0.18, representing a -57.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Telesis Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Telesis Bio

All Key Metrics — Telesis Bio